Andrew Simpson is the CEO and Chairman of Heart Test Laboratories, Inc., a position he has held since March 2022. With an MBA and a strong background in management, he's seasoned in leading various business sectors. Before his current role,...

Andrew Simpson is the CEO and Chairman of Heart Test Laboratories, Inc., a position he has held since March 2022. With an MBA and a strong background in management, he's seasoned in leading various business sectors. Before his current role, he led The Peel Group, a large private company in the UK with around $8 billion in assets. Simpson is known for his hands-on approach; he’s actively involved in improving company performance metrics to drive growth. His previous experience includes pivotal roles in companies like Speedy Hire, where he helped it grow into a FTSE 250 company. Right now, as head of a company developing medical devices, he's pushing for FDA clearance for new technology. Interestingly, in 2023, his compensation was primarily in cash, reflecting a performance-driven strategy with a total of $264,139. Despite being relatively new in this role, he's already made significant impacts on the company and its operations.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

H

Andrew Simpson

CEO of Heart Test Laboratories, Inc.

Education

MBA from Harvard Business School

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

May 15, 1974 - 51 years ago

CEO of Heart Test Laboratories, Inc. for

2 years 2 months (Mar 2023 - Present)

Previous Experience

CEO of Kyngstone Limited

Rivals

Competitors/colleagues of Andrew Simpson

Holdings

See how much did Andrew Simpson make over time.

Andrew Simpson has been active in trading shares of Heart Test Laboratories, participating in several insider trades recently. Notably, he made trades worth $25.92K on August 1, 2024, and another for $22.48K on September 1, 2024. His stock holdings have...

Andrew Simpson has been active in trading shares of Heart Test Laboratories, participating in several insider trades recently. Notably, he made trades worth $25.92K on August 1, 2024, and another for $22.48K on September 1, 2024. His stock holdings have seen fluctuations, indicating a significant engagement with the company's financial health. At present, a portion of his wealth is tied to Heart Test Laboratories, and as of 2022, his financial stake was highlighted by the company's $1.5 million in convertible promissory notes that converted to shares upon IPO. His trading activity suggests he is closely monitoring the market and may be preparing for future developments as the company progresses toward FDA clearance.

Insider Trading

See recent insider trades of Andrew Simpson.

No insider trades found for this CEO.

Compensation History

See how much did Andrew Simpson make over time.

In 2023, Andrew Simpson received a total compensation of $264,139 as CEO of Heart Test Laboratories. His salary was $234,139 coupled with a performance-based bonus of $30,000. This structure emphasizes the company's focus on results. Interestingly, there were no stock options or grants in 2023 as the company shifted to cash compensation. In the previous year, he had a much lower compensation of $144,806, indicating substantial growth in his pay as the company looks to incentivize its leadership to meet ambitious targets. This approach ties his earnings directly to company performance, providing a clear alignment of interests with shareholders.

Year

2023

Total Compensation

$264.14K

Salary

$234.14K

Board Justification

The company aims to align executive compensation with performance metrics that drive shareholder value, focusing on cash compensation and performance bonuses rather than equity grants in 2023.

Bonus

$30.00K

Board Justification

The bonus is based on performance metrics set by the Compensation Committee, which include company revenue growth and operational efficiency targets for the fiscal year 2023.

Other

$0.00

Board Justification

No additional compensation was reported outside of salary and bonus.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards vested in 2023 as the focus was on cash compensation and bonuses.

Performance Metrics

Performance metrics include revenue growth and operational efficiency targets.